ORPHA:251663
Anaplastic oligoastrocytoma, dual genotype
Also known as: Anaplastic oligoastrocytoma, dual genotype NEC · Anaplastic oligoastrocytoma, dual genotype, not elsewhere classified · aMOA
Publications
1,821
Trials
36
Interventional, condition-specific
Researchers
1,400
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare and aggressive glial tumor of the central nervous system, that usually presents in adults with , is most often located in the cerebral hemispheres and that is associated with a very poor prognosis.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016703
- UMLS:C0431108
- NCIT:C6959
Additional Mondo synonyms (3)
WHO grade III mixed glioma · anaplastic mixed glioma · anaplastic oligoastrocytoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,821 matched papers (852 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
36 matched on ClinicalTrials.gov (2 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
11
Drugs / clinical candidates · MONDO_0016703
- LOMUSTINE·phase 3
- PROCARBAZINE·phase 3
- VINCRISTINE·phase 3
- BUSULFAN·phase 2
- CARMUSTINE·phase 2
- CETUXIMAB·phase 2
- LEFLUNOMIDE·phase 2
- TEMOZOLOMIDE·phase 2
- THIOTEPA·phase 2
- SORAFENIB·phase 1
- AXL-1717·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,821
1,821 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,821 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
852 in the last 10 years · low confidence
Phrase hits: 1,821 · MeSH hits: 0
Who's working on it?
1,400
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Wang J6 papers · 2023
Department of Surgery of Spine and Spinal Cord, Henan Provincial People's Hospital, Henan Province Intelligent Orthopedic Technology Innovation and Transformation International Joint Laboratory, Henan Key Laboratory for Intelligent Precision Orthopedics, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Henan Zhengzhou, China.
Papers in Europe PMC - 02Wang Y6 papers · 2023
Department of Endocrinology, The Ninth People's Hospital of Chongqing, Chongqing, 400799, China. wangyi-med@sohu.com.
Papers in Europe PMC - 03Huang Y5 papers · 2025
Guangdong Provincial Key Laboratory of Infectious Disease and Molecular Immunopathology, Shantou University Medical College, Shantou, China.
Papers in Europe PMC - 04Li H4 papers · 2025
Department of Neurosurgery, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China.
Papers in Europe PMC - 05Li J4 papers · 2025
Department of Clinical Research, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
Papers in Europe PMC - 06Lin S4 papers · 2026
Department of Neurosurgery, Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing 100500, China. Email: linsong2005@126.com.
Papers in Europe PMC - 07Liu J4 papers · 2024
Department of Neurosurgery, Guizhou Provincial People's Hospital, Guiyang, P.R. China.
Papers in Europe PMC - 08Yang Z4 papers · 2026
Pathology Department of the First Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, People's Republic of China.
Papers in Europe PMC - 09Zhang H4 papers · 2022
Department of Pediatrics , Baylor College of Medicine, Houston, TX,
Papers in Europe PMC - 10Chang JH3 papers · 2023
Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea. ; Neuro-Oncology Clinic, Yonsei University College of Medicine, Seoul, Korea. ; Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
36
interventional trials for this specific condition
36 interventional trials matched this specific condition name; 2 currently recruiting in our sample. 26 trials are registered for oligoastrocytoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026
36 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 96.4th percentile).
low confidence · 96.4th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
36 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT02800486·RECRUITING·Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Not reviewed·Conditions: Glioblastoma · Anaplastic Astrocytoma · Anaplastic Oligoastrocytoma · Glioma·Matched via name phrase
- NCT04623931·RECRUITING·Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Not reviewed·Conditions: Anaplastic Astrocytoma, IDH-Wildtype · Anaplastic Oligoastrocytoma · Anaplastic Oligodendroglioma · Diffuse Astrocytoma, IDH-Wildtype·Matched via name phrase
Broader category: oligoastrocytoma
26
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Observational and natural-history studies
3 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 1 · after dedupe 1 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 1 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (1)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Anaplastic oligoastrocytoma, dual genotype — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Anaplastic oligoastrocytoma, dual genotype" OR "Anaplastic oligoastrocytoma, dual genotype NEC" OR "Anaplastic oligoastrocytoma, dual genotype, not elsewhere classified" OR "WHO grade III mixed glioma" OR "anaplastic mixed glioma" OR "anaplastic oligoastrocytoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Anaplastic oligoastrocytoma, dual genotype" OR "Anaplastic oligoastrocytoma, dual genotype NEC" OR "Anaplastic oligoastrocytoma, dual genotype, not elsewhere classified" OR "WHO grade III mixed glioma" OR "anaplastic mixed glioma" OR "anaplastic oligoastrocytoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 36 interventional · 3 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"oligoastrocytoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: aMOA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
- Publication count (1821) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T10:51:57.319Z
